Tuberculosis and the Tubercle Bacillus, Second Edition

Editors: William R. Jacobs, Jr.1, Helen McShane2, Valerie Mizrahi3, Ian M. Orme4
Affiliations: 1: Department of Immunology and Microbiology, Albert Einstein School of Medicine, New York, New York; 2: Cellular Immunology and Vaccine Development Group, Nuffield Department of Medicine, Jenner Institute, University of Oxford, Oxford, United Kingdom; 3: Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Faculty of Health Sciences, Rondebosch, South Africa; 4: Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado
Content Type: Monograph
Format: Hardcover
Publication Year: 2017

Category: Microbial Genetics and Molecular Biology; Bacterial Pathogenesis

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Tuberculosis and the Tubercle Bacillus is now available on Wiley.com
Members, use the code ASM20 at check out to receive your 20% discount.

One third of the world’s population is infected with tuberculosis (TB), with about 10 million new cases annually. To combat TB and its agent, , the World Health Organization launched The End TB Strategy, which aims to slash the suffering and cost of TB by 2035.

This makes the second edition of , edited by Jacobs, McShane, Mizrahi, and Orme, an extremely valuable resource for scientists and clinicians. The editors have gathered their colleagues from around the world to present the latest on the molecular biology of and related species, the host-pathogen interactions that enable invasion, and the host’s immune response to infection. The basic, clinical, and translational research presented in this book supports the goals of WHO’s End TB Strategy by driving toward the development of effective vaccines, rapid molecular diagnostics, and anti-TB drugs.

  • Understand the innate and adaptive immune response to infection, its study in established animal models, and how this information is being used to develop new vaccines against TB.
  • Learn the challenges and methods for evaluating new drugs in preclinical trials with a focus on drugs that work against “persisters” and those that act on the electron transport complex and ATP synthase of .
  • Review new diagnostic tools that are simple, rapid, affordable, specific, sensitive, and safe, including molecular-based diagnostic methods such as GeneXpert MTB/RIF.
  • Explore current research on the molecular mechanisms that uses to evade the immune system, enter a state of nonreplicating persistence, and become reactivated.

The second edition of presents the latest research on a microorganism that is exquisitely well adapted to its human host. This pathogen continues to confound scientists, clinicians, and public health specialists, who will all find much valuable information in this comprehensive set of reviews.

Book Summary

Loading full text...

Full text loading...

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error